Sleep Disorders

A look back at clinician-led features from 2025 that examine the questions, data, and decisions shaping neurologic care.

Explore the transformative buzzwords in neurology for 2025, highlighting advancements in AI, gene therapy, personalized treatment, and neuroplasticity.

Here's some of what is coming soon to NeurologyLive® this week.

Here's some of what is coming soon to NeurologyLive® this week.

TRN-257, a treatment in development for adults with narcolepsy and idiopathic hypersomnia, is designed to reduce daily sodium exposure relative to existing higher-sodium therapies.

Here's some of what is coming soon to NeurologyLive® this week.

Here's some of what is coming soon to NeurologyLive® this week.

Here's some of what is coming soon to NeurologyLive® this week.

Vaishal Shah, MD, MPH, FAASM, FAAP, center director of the Sleep Disorders Center at Cleveland Clinic, spoke on the changes in how obstructive sleep apnea is treated, moving away from CPAP to more novel approaches.

Here's some of what is coming soon to NeurologyLive® this week.

Centessa Pharmaceuticals reveals promising early-stage results for its orexin receptor 2 agonists, ORX750 and ORX142, targeting neurologic sleep disorders.

New trial results reveal alixorexton's significant efficacy in treating narcolepsy type 2, marking a potential breakthrough in sleep medicine.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 10, 2025.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 3, 2025.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 26, 2025.

Dionne Morgan, MD, a sleep medicine physician at Baptist Health Miami Cardiac & Vascular Institute, provided commentary on World Narcolepsy Day, highlighting challenges in diagnosis and treatment, evolution in therapeutics, and combating comorbidities.

New research highlights daridorexant's effectiveness in improving sleep for women experiencing insomnia during menopause, showcasing significant benefits in sleep quality.

The vice chair of neurology at West Virginia University reflected on receiving the AUPN Leadership Award, addressing challenges in academic neurology and the evolving responsibilities of vice chairs in advancing departmental goals.

A recent study reveals dual orexin receptor agonists (DORAs) show significantly lower abuse potential compared to traditional insomnia medications.

The VP of clinical development at Alkermes detailed phase 2 results for alixorexton, an oral, selective orexin 2 receptor agonist, in narcolepsy type 1, including benefits for fatigue, cognition, and weakness.

Here's some of what is coming soon to NeurologyLive® this week.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the link between iRBD and neurodegeneration.

A recent Canadian study reported similar trends in polysomnography and positive airway pressure initiation over a decade between patients with Parkinson disease and matched controls.